Biology Reference
In-Depth Information
distance in IC patients. Inhibition of adenosine uptake by cilostazol may also
contribute to its efficacy and safety. While PDE3 inhibition is still being pursued
for the treatment of IC, improved treatment in the future may result from pharma-
cological targeting of multiple pathways. Finally, an optimal pharmacological
treatment should relieve both the symptoms of IC and reduce cardiovascular
morbidity and mortality.
Acknowledgments We thank Dr. Narendra Tandon for assisting the preparation of this article.
References
Ambrus JL, Ambrus CM, Taheri SA, Gastpar H, Reddington MM, Taheri P, Kahn EA,
Schattman GL, Dean LS, Moore RH (1984) Red cell flexibility and platelet aggregation in
patients with chronic obstructive vascular disease (COAD) and study of
therapeutic
approaches. Angiology 35:418-426
Ashikaga T, Strada SJ, Thompson WJ (1997) Altered expression of cyclic nucleotide phosphodi-
esterase isozymes during culture of aortic endothelial cells. Biochem Pharmacol 54:1071-1079
Askew CD, Green S, Walker PJ, Kerr GK, Green AA, Williams AD, Febbraio MA (2005) Skeletal
muscle phenotype is associated with exercise tolerance in patients with peripheral arterial
disease. J Vasc Surg 41:802-807
Barker GA, Green S, Askew CD, Green AA, Walker PJ (2001) Effect of propionyl-L-carnitine on
exercise performance in peripheral arterial disease. Med Sci Sports Exerc 33:1415-1422
Barton M, Haudenschild CC (2001) Endothelium and atherogenesis: endothelial therapy revisited.
J Cardiovasc Pharmacol 38(Suppl 2):S23-S25
Beebe HG, Dawson DL, Cutler BS, Herd JA, Strandness DEJ, Bortey EB, Forbes WP (1999)
A new pharmacological treatment for intermittent claudication: results of a randomized,
multicenter trial. Arch Intern Med 159:2041-2050
Bender AT, Beavo JA (2006) Cyclic nucleotide phosphodiesterases: molecular regulation to
clinical use. Pharmacol Rev 58:488-520
Berman W Jr, Berman N, Pathak D, Wood SC (1994) Effects of pentoxifylline (Trental) on blood
flow, viscosity, and oxygen transport in young adults with inoperable cyanotic congenital heart
disease. Pediatr Cardiol 15:66-70
Boger RH, Bode-Boger SM, Thiele W, Creutzig A, Alexander K, Frolich JC (1998) Restoring
vascular nitric oxide formation by L-arginine improves the symptoms of intermittent claudica-
tion in patients with peripheral arterial occlusive disease. J Am Coll Cardiol 32:1336-1344
Brass EP, Anthony R, Cobb FR, Koda I, Jiao J, Hiatt WR (2006) The novel phosphodiesterase
inhibitor NM-702 improves claudication-limited exercise performance in patients with periph-
eral arterial disease. J Am Coll Cardiol 48:2539-2545
Bregar U, Poredos P, Sabovic M, Jug B, Sebestjen M (2009) The influence of atorvastatin on
walking performance in peripheral arterial disease. Vasa 38:155-159
Cheung P, Yang G, Boden G (2003) Milrinone, a selective phosphodiesterase 3 inhibitor,
stimulates lipolysis, endogenous glucose production, and insulin secretion. Metabolism 52:
1496-1500
Chiu PJ, Vemulapalli S, Chintala M, Kurowski S, Tetzloff GG, Brown AD, Sybertz EJ (1997)
Inhibition of platelet adhesion and aggregation by E4021, a type V phosphodiesterase inhibitor,
in guinea pigs. Naunyn Schmiedebergs Arch Pharmacol 355:463-469
Choi JM, Shin HK, Kim KY, Lee JH, Hong KW (2002) Neuroprotective effect of cilostazol against
focal cerebral ischemia via antiapoptotic action in rats. J Pharmacol Exp Ther 300:787-793
